All In MedTech

Device Trial Radar · NCT07652164

Water Vapor Ablation for Grade Group 3 Prostate Cancer

Vanquish® Water Vapor Ablation for Grade Group 3 PrOstate CanceR: A Multicenter Single Arm Study

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Aug 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Francis Medical Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 16, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation System ("Vanquish") in participants with Grade Group 3 (GG3) intermediate-risk prostate cancer. Participants will undergo therapy with the Vanquish System and complete follow up visits at 7 days, 6 weeks, 6 months, 12 months, 18 months, and 24 months.

Conditions

  • Prostate Cancer

Interventions

  • Water Vapor AblationDevice

    Water vapor ablation delivered transurethrally in patients with Grade Group 3 (GG3) intermediate risk prostate cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ablative Efficacy 6-Months Post AblationTime frame: 6 months post procedure.
  2. Rate of Serious Adverse Events Through 6-MonthsTime frame: From the start of the Vanquish procedure through 6-months post procedure.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.